Posted by Michael Wonder on 01 Sep 2021
FDA approves zanubrutinib for Waldenström’s macroglobulinaemia
1 September 2021 - On 31 August 2021, the Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinaemia.
Zanubrutinib was investigated in ASPEN, a randomised, active control, open-label trial, comparing zanubrutinib and ibrutinib in patients with MYD88 L265P mutation Waldenström’s macroglobulinaemia.
